# Physiological Changes and Health Impacts

### **Cardiovascular Effects and Safety of Psychedelic Medicine**

Classic psychedelics—such as **psilocybin, LSD, DMT/ayahuasca, and mescaline**—are powerful psychoactive compounds that modulate perception, emotion, and cognition through their action on the **serotonergic system**, primarily the **5-HT₂A receptor**. Once considered fringe, these substances are now at the forefront of psychiatric innovation, showing **promising efficacy in treatment-resistant depression, PTSD, addiction, and end-of-life anxiety**.\
Historically used in healing and spiritual contexts for millennia, their reemergence in science and medicine—the so-called **“psychedelic renaissance”**—marks a return to systematic, evidence-based exploration of their therapeutic potential.

#### **Mechanisms of Cardiovascular Action**

The cardiovascular effects of psychedelics are primarily mediated by their influence on **serotonin and the autonomic nervous system**:

* **Serotonergic System:**\
  Psychedelics act as **agonists at 5-HT₂A, 5-HT₂B, and 5-HT₄ receptors**, present in both neural and cardiac tissue. Activation of these receptors can influence **vasoconstriction**, **platelet aggregation**, and **heart rhythm**. Serotonin itself causes direct **vascular constriction**, and excessive stimulation of 5-HT₂B receptors has been linked in other drugs to **valvulopathy**—though current evidence does **not** indicate such risk with classic psychedelics at therapeutic doses.
* **Sympathomimetic Effects:**\
  Through indirect stimulation of **adrenergic, dopaminergic, and histaminergic** pathways, psychedelics can increase **heart rate and blood pressure** transiently. These effects are typically mild, short-lived, and well tolerated in healthy individuals.

***

#### **Findings from Experimental and Clinical Studies**

* **Acute Cardiovascular Response:**\
  Most clinical trials report **transient increases in heart rate and blood pressure**, generally within a mild and safe range that **does not require medical intervention**.<sup>1, 2</sup>
  * *Psilocybin:* Mild, dose-dependent increases in cardiovascular activity; QTc prolongation has been noted but remains clinically insignificant.
  * *LSD:* Produces temporary pressor responses; lower doses often show no significant changes in vital signs.
  * *DMT/Ayahuasca:* Causes short-lived elevations in heart rate and blood pressure without adverse outcomes in controlled settings.
* **Electrophysiological Safety:**\
  No major **electrocardiographic abnormalities** or **hERG channel inhibition** have been documented at standard clinical doses of psilocybin or LSD. However, **non-classic psychedelics** such as ibogaine carry higher risk for **QT prolongation** and **arrhythmia**, requiring strict medical monitoring.
* **Vasoconstriction and Vascular Reactivity:**\
  High-dose or recreational use may induce **strong vasoconstriction** via 5-HT₂A receptor activation. While rare, **severe vasospasm** has been reported in extreme cases of LSD or psilocybin overuse.
* **Valvulopathy Risk:**\
  Despite theoretical concerns due to 5-HT₂B receptor activity, **no clinical or preclinical evidence** links classic psychedelics to heart valve disease. Animal and human studies with ayahuasca show **no cardiac tissue abnormalities** following administration.

### **Respiratory**

Ventilation changes during breathwork correlate with the depth of altered experience.

### **Neuroendocrine**

Cortisol levels often drop, while **oxytocin** spikes during MDMA use or loving-kindness meditation.

### **Neuroplasticity**

Increases in **BDNF**, **synaptic density**, and **structural brain connectivity** are observed across several ASC modalities.

### **Mental Health**

Controlled studies show sustained improvements in **depression, anxiety, PTSD,** and **addiction**, often exceeding traditional interventions.

### **Personality and Well-Being**

Post-ASC increases in **openness, emotional resilience,** and **life satisfaction** are consistently reported.

### **Physical Health**

Enhanced **immune function**, **pain relief**, and **sleep quality** are common outcomes.

**Risks:** ASCs can occasionally evoke **challenging psychological experiences**, **transient anxiety**, or in rare cases, **persistent psychosis** in predisposed individuals. Physiological risks include **cardiovascular strain** and **syncope** during intense breathwork. Proper screening, preparation, and integration are essential to ensure safety and therapeutic value.

***

### References

1. Nahlawi, A.; Ptaszek, L. M.; Ruskin, J. N. Cardiovascular effects and safety of classic psychedelics. *Nat Cardiovasc Res* 2025, *4* (2), 131-144. DOI: 10.1038/s44161-025-00608-2  From NLM Medline.
2. Wsol, A. Cardiovascular safety of psychedelic medicine: current status and future directions. *Pharmacol. Rep.* 2023, *75* (6), 1362-1380. DOI: 10.1007/s43440-023-00539-4  From NLM Medline.